NEW YORK – With its recent acquisition of San Francisco startup Singular Bio, Invitae is joining others that are aiming to bring down the cost of genetic testing, starting with cell-free DNA-based noninvasive prenatal screening.
The technology will also lend itself to other applications that involve cell-free nucleic acids, such as liquid biopsy cancer tests.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
